- Home
- ATAI vs HURA Comparison
ATAI vs HURA Comparison
Compare ATAI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATAI | HURA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 112.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | HURA |
|---|---|---|
| Price | $3.35 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $15.57 | $10.00 |
| AVG Volume (30 Days) | ★ 4.6M | 721.8K |
| Earning Date | 03-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $308,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.15 | $0.41 |
| 52 Week High | $6.73 | $4.41 |
Technical Indicators
Market Signals| Indicator | ATAI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 55.72 |
| Support Level | $3.06 | $1.66 |
| Resistance Level | $4.30 | $2.20 |
| Average True Range (ATR) | 0.21 | 0.20 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 9.14 | 26.80 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.